Plerixafor, given on day 4 of G-CSF treatment is more effective than G-CSF alone in mobilizing hematopoietic progenitor cells. We tested a strategy of preemptive plerixafor use following assessment of the peak mobilization response to 5 days of G-CSF. Patients were eligible for plerixafor if, on day 5 of G-CSF, there were o7 circulating CD34 þ cells/mL or if o1.3 Â 10 6 CD34 þ cells/kg were collected on the first day of apheresis. Plerixafor (0.24 mg/kg s.c.) was given on day 5 of G-CSF followed by apheresis on day 6. This was repeated for up to two additional doses of plerixafor. The primary end point of the study was the percentage of patients who collected at least 2 Â 10 6 CD34 þ cells/kg. Twenty candidates for auto-SCT enrolled on the trial. The circulating CD34 þ cell level increased a median of 3.1 fold (range 1 --8 fold) after the first dose of plerixafor and a median of 1.2 fold (range 0.3 --6.5 fold) after the second dose of plerixafor. In all, 15 out of 20 (75%) patients achieved the primary end point. In conclusion, the decision to administer plerixafor can be delayed until after the peak mobilization response to G-CSF has been fully assessed.
INTRODUCTION
The use of high-dose chemotherapy with autologous PBSC rescue for treatment of high-risk malignancies is contingent upon collection of a minimum CD34 þ cell dose of approximately 2 Â 10 6 /kg. Inadequate mobilization of CD34 þ cells results in a failed collection in up to 30% of candidates for auto-SCT. 1 --5 Plerixafor reversibly inhibits binding of stromal cell-derived factor 1 alpha to the chemokine receptor CXCR4 resulting in mobilization of BM hematopoietic progenitor cells. 6 --8 Phase 3 studies demonstrate that when given in the evening of day 4 of G-CSF treatment, plerixafor significantly improves the chance of successful PBSC collection compared with G-CSF alone in patients with multiple myeloma and non-Hodgkin's lymphoma. 1, 2 The drug has international regulatory approval for this purpose, and is now widely used.
The peak mobilization response to G-CSF alone occurs on the fifth day of administration. 9, 10 Therefore, the current standard of plerixafor administration on day 4 of G-CSF means that the decision to administer this agent occurs before the peak mobilization response to G-CSF can be assessed. Routine use of plerixafor on day 4 of G-CSF treatment may not be necessary because many patients will mobilize CD34 þ cells adequately in response to G-CSF alone. For the patients that fail single agent G-CSF mobilization, a second mobilization session with the addition of plerixafor dosed on day 4 of G-CSF can rescue 63% of patients. 11 In the context of a prospective, single center phase 2 study, we tested the hypothesis that plerixafor could be used to rescue poor mobilizers on day 5 of G-CSF thereby avoiding a second apheresis session.
MATERIALS AND METHODS

Protocol eligibility
Protocol eligibility included patients aged 18 --75 years with a diagnosis of multiple myeloma, non-Hodgkin's or Hodgkin's lymphoma who were candidates for high-dose chemotherapy and autologous stem cell rescue. Patients must have recovered from acute toxic effects of prior chemotherapy, and achieved adequate hematologic recovery defined by an ANC of 41.0 Â 10 9 /L and a platelet count of 75 Â 10 9 /L. Patients were excluded if they had failed previous attempts at PBSC collection, or had prior radioimmunotherapy (Ibritumomab Tiuxetan or Tositumomab). Patients were screened for protocol participation prior to, or during, G-CSF mobilization. Patients were deemed eligible for protocol participation if, on day 5 of G-CSF treatment, the circulating CD34 þ cell level was o7/mL. These patients did not undergo apheresis on day 5 of G-CSF treatment, as historically, at our center, the poor CD34 þ cell yield does not justify the expense of the procedure. In addition, patients with 7 --20 circulating CD34 þ cells/mL on day 5 of G-CSF treatment were also eligible for protocol therapy if o1.3 Â 10 6 CD34 þ cells/kg were collected on the first day of apheresis (Figure 1) . Justification for targeting patients with 7 --20 circulating CD34 þ cells for preemptive plerixafor therapy comes from review of outcomes from a historical cohort. During a 12-month period, five patients (multiple myeloma, n ¼ 4; non-Hodgkin's lymphoma, n ¼ 1) were identified. Two of the five patients achieved a transplantable stem cell dose of X2 Â 10 6 CD34 þ cells/kg. Three of the five patients failed to collect the minimum cell dose and thus may benefit from an alternative mobilization strategy.
Study design
The study was approved by the institutional review board of the Duke University School of Medicine. Patients from the Duke Adult Stem Cell Transplant Program were prospectively screened up to 3 days prior to the commencement of G-CSF mobilization for enrollment to the study. The study was open for accrual over a period of 15 months. All patients provided written informed consent prior to participation. The protocol schema is demonstrated in Figure 1 . All patients were treated with G-CSF 10 mg/kg s.c. qAM. Consented patients received dose 1 of plerixafor 0.24 mg/kg s.c. on day 5 of G-CSF treatment at approximately 2200 hours.
The process of evening dosing with plerixafor was followed the next morning by administration of G-CSF, and a 3-blood volume ( ± 20%) apheresis procedure on a COBE Spectra (Gambro BCT, Lakewood, CO, USA) was repeated for up to a total of 3 days or until X5 Â 10 6 cells/kg were collected. Peripheral blood CD34 þ cell counts were determined by flow cytometry at the Duke University Medical Center using the ISHAGE protocol. Toxicities were monitored and recorded from the time of plerixafor administration until completion of apheresis using the WHO common toxicity criteria version 3.
Statistical considerations
This is a phase 2 observational study. The primary end point of the study was the percentage of patients who yielded least 2 Â 10 6 CD34 þ cells/kg. The sample size was determined to be of adequate size to justify expanded study of the pharmacoeconomic properties of preemptive plerixafor usage. Although there were no specific sample size requirements for the study, a sample size of 20 was chosen as it provided a 95% confidence interval for the percentage of patients reaching the primary end point with a width not wider than ± 22.0%, assuming a success rate of 50%.
RESULTS
Patient characteristics
Patient characteristics are outlined in Table 1 . During the 15-month time period of study activation, a total of 38 patients were screened for protocol participation. Eighteen patients with a median age of 58 years (range 24 --76) and a median of 1 prior regimen (range 1 --3) were screened for study participation but did not meet the eligibility criteria because of there being 420 peripheral blood CD34 þ cells or 7 --20 peripheral blood CD34 þ cells with a day 1 apheresis yield of X1.3 Â 10 6 CD34 þ cells/kg. All the 18 patients achieved the minimum CD34 þ cell yield of 2 Â 10 6 CD34 þ cells/kg. All patients achieved neutrophil (ANC 4500) and 17 out of 18 achieved platelet (420 000) engraftment at a median time of 12 and 16 days, respectively, following transplantation. The time to neutrophil and platelet engraftment in patients who did not receive plerixafor did not differ from that observed in the study patients (12 vs 11 days, P ¼ 0.6; 18 vs 19 days, P ¼ 0.7, respectively). Twenty patients with a median age of 61 years (range 39 --70) met the eligibility criteria for enrollment in the protocol and were available for analysis. The patients were candidates for high-dose chemotherapy with autologous stem cell rescue for treatment of non-Hodgkin's lymphoma (n ¼ 10), Hodgkin's disease (n ¼ 2) or multiple myeloma (n ¼ 8). The patients had a median of 2 courses of prior chemotherapy (range 1 --3). Six out of eight patients (63%) with multiple myeloma had a median of 5 cycles (range 4 --15) of lenalidomide prior to undergoing stem cell mobilization. Eleven patients (55%) met the eligibility criteria owing to mobilization of o7 CD34 þ cells/mL following five doses of G-CSF. The remainder met the eligibility criteria owing to collection of o1.3 Â 10 6 CD34 þ cells/kg body weight following five doses of G-CSF treatment and a 3-blood volume apheresis session. Patients received a median of 2 doses of plerixafor on study (range 1 --3).
Mobilization response to plerixafor beginning on day 5 of G-CSF administration The response to preemptive dosing of plerixafor is shown in Figure 2 . The median circulating CD34 þ cell level on day 5 of G-CSF administration was 6.5/mL (range o1 --16/mL). The median circulating CD34 þ cell level on day 6 of G-CSF administration, following dose 1 of plerixafor, was 19.5/mL (range o1 --55/mL), representing a median 3.1-fold (range 1 --8 fold) increase in circulating CD34 þ cell level between day 5 and day 6 of G-CSF administration. Thirteen patients received a second dose of plerixafor on day 6 of G-CSF administration. The median circulating CD34 þ cell level measured the following morning was 10/mL (range 2 --26/mL), representing a median 1.2-fold (range 0.3 --6.5 fold) change in circulating CD34 þ cells from the baseline measurement following 5 days of G-CSF administration and a median 0.7-fold change in circulating CD34 þ cells from the level measured after the first dose of plerixafor. Two patients received a third dose of plerixafor on day 7 of G-CSF mobilization. This resulted in a circulating level of CD34 þ cells on day 8 of G-CSF administration that was 1 fold and 1.8 fold different from the baseline day 5 measurement, respectively. Neither of these patients achieved a circulating CD34 þ cell level high enough to justify apheresis.
CD34 þ cell yield In all, 15 out of 20 patients (75%) who had a suboptimal mobilization response on day 5 of G-CSF treatment achieved the primary end point of the study by providing X2 Â 10 6 CD34 þ cells/kg. An additional patient (patient no. 17) responded to preemptive plerixafor, showing an increase from 5 CD34 þ cells/ mL on day 5 of G-CSF to 18 CD34 þ cells/mL on day 6 of G-CSF following dose 1 of plerixafor. However the patient did not undergo apheresis due to inadequate venous access. Eleven patients had o7 CD34 þ cells/mL after five daily doses of G-CSF and thus had apheresis deferred until the following day. Following the first dose of plerixafor, these patients had a median of 18 CD34 þ cells/mL (range 1 --55 CD34 þ cells/mL), representing a median 4-fold (range 1 --8 fold) increase from the prior day. The median cumulative CD34 þ cell dose recovered from all study patients was 2.3 Â 10 6 CD34 þ cells/kg (range 0 --6 Â 10 6 CD34 þ cells/kg). In all, 4 out of 20 patients (20%) failed preemptive dosing of plerixafor and thus had inadequate collection of peripheral blood CD34 þ cells.
Of the four patients who failed to respond to preemptive dosing of plerixafor, all subsequently went on to provide a transplantable CD34 þ cell dose with additional mobilization sessions. Two were collected with chemotherapy mobilization and two with a second G-CSF/plerixafor combination.
There were five patients with multiple myeloma who were enrolled in the study and had prior therapy with lenalidomide (median 5 cycles, range 4 --15 cycles). Three of the five patients were successfully rescued with plerixafor dosing on protocol.
Toxicity and engraftment There were no toxicities from plerixafor therapy that exceeded WHO grade I. Hyperleukocytosis (WBC 460 Â 10 9 mL) was not observed in any of the subjects. Fourteen out of fifteen patients from whom X2 Â 10 6 CD34 þ cells/kg were obtained subsequently underwent high-dose chemotherapy and autologous stem cell rescue. One patient with multiple myeloma opted for a delay in high-dose therapy. All transplanted patients who received autologous cells collected with the combination of G-CSF and plerixafor experienced prompt hematopoietic recovery. The median time to neutrophil engraftment (4500/mL) and platelet engraftment (450 000/mL) was 11 days and 19 days, respectively, following transplantation. There were no cases of primary or secondary graft failure.
DISCUSSION
Twenty patients with a pre-defined suboptimal mobilization response to five daily doses of G-CSF 10 mg/kg were enrolled on this study. With the use of preemptive plerixafor dosing, a transplantable stem cell dose was obtained from 15 out of 20 patients (75%), preventing the need for a second mobilization session. Consistent with observations from larger phase 3 studies, plerixafor administration proved to be safe and effective with no significant toxicities associated with its administration. All patients undergoing SCT using cells collected with the aid of plerixafor experienced prompt and robust engraftment.
In an era of continued escalation in the cost of health care, it is critical to study new methods of blending both optimal and costeffective treatment approaches. There are multiple opportunities for health care costs to escalate when candidates for autologous SCT are poor mobilizers. Some patients will require additional days of apheresis that, even then, may not provide an adequate CD34 þ cell dose. Other patients will require a second stem cell mobilization and apheresis session using G-CSF alone or in combination with chemotherapy or possibly a BM harvest procedure performed in the operating room. Patients transplanted with suboptimal CD34 þ cell dose also experience prolonged time to engraftment with increased needs for transfusion support, antibiotics and hospitalization. Finally, there is the emotional toll placed on the patient when optimal therapy (high-dose therapy with autologous stem cell rescue) cannot be provided, because of the inability to collect adequate numbers of hematopoietic progenitors. Plerixafor, used in a judicious and cost-effective manner may reduce the costs associated with a poor mobilization response.
Using the average wholesale price as reported in the Redbook 2009 edition, Shaughnessy et al.
12 estimated the average sale price for a vial (a single dose for a patient p70 kg) of plerixafor to be $6250.00. Despite the high cost, plerixafor has the potential to provide considerable cost savings by reducing both the number of apheresis sessions and the number of failed mobilization attempts. Additional cost savings could be achieved if plerixafor usage is limited to patients who have an inadequate mobilization response to G-CSF alone. 13 The current standard of care is to administer plerixafor on day 4 of G-CSF. However, the peak mobilization response to G-CSF occurs on day 5 of s.c. administration at a dose of 10 mg/kg. 9, 10 Therefore, administration of plerixafor on day 4 of G-CSF comes before peak mobilization of G-CSF can be determined. The rational for the preemptive plerixafor usage described in this study is that it allows for peak mobilization of G-CSF to be assessed in all patients prior to plerixafor usage.
The impact of plerixafor on stem cell mobilization was examined in the context of a phase 3 randomized trial comparing the combination of G-CSF and day 4 dosing of plerixafor with G-CSF alone in autologous SCT candidates with non-Hodgkin's lymphoma. 1 For patients randomized to the G-CSF/plerixafor mobilization, 87% provided X2 Â 10 6 CD34 þ cells/kg compared with 47% of those patients who received G-CSF alone. Patients from either arm who failed to mobilize (o0.8 Â 10 6 CD34 þ cells/ kg in two collections or o2 Â 10 6 CD34 þ cells in four collections) were offered a second rescue mobilization at a later date using plerixafor given on day 4 of G-CSF in an open-label fashion. As reported by Micallef et al., 11 successful collection (42 Â 10 6 CD34 þ cells/kg) was achieved in 63% of patients who failed mobilization in the G-CSF-alone arm. In the present study, 75% of the poor mobilizers were successfully collected using a preemptive plerixafor rescue approach that does not require a second session of mobilization and apheresis. Important differences in the two studies should be noted. For our study, patients with non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma were eligible for participation, whereas the Micallef study only included patients with nonHodgkin's lymphoma. Our study mandated determination of a 'poor mobilizer' based on the circulating CD34 þ level after five daily doses of G-CSF and 0 or 1 apheresis session. In contrast, the Micallef study allowed for 2 --4 sessions of apheresis before declaring the patient a poor mobilizer. Thus, the latter study identified a more accurately defined population of poor mobilizers. But even with the acknowledgment that with further apheresis sessions, some of the study patients may have provided an adequate CD34 þ cell dose without the addition of plerixafor treatment, there remain many advantages to an up-front preemptive plerixafor rescue approach. First is that it reduces the likelihood of a costly and more time consuming second session of mobilization. Second, those patients who responded adequately to G-CSF alone do not incur the additional and unnecessary cost of plerixafor administration.
In the time since plerixafor has become available for clinical use, many groups have described novel approaches to utilization of this agent following cytokine only, or chemotherapy plus cytokine mobilization strategies. 13 --17 Two groups have proposed a preemptive strategy for plerixafor administration based on circulating levels of CD34 þ cells on the fourth day of G-CSF administration. 13, 17 The advantage of this approach is that the peak mobilizing effect of both plerixafor and cytokine is synchronized. The disadvantage is that it may be premature to designate a patient as a 'poor mobilizer' and in need of preemptive plerixafor after only four doses of cytokine.
We conclude that a mobilization rescue strategy consisting of preemptive plerixafor given on day 5 of G-CSF administration in patients who demonstrate an inadequate mobilization response to G-CSF alone is safe and effective in the majority of patients. This preemptive strategy allows for the peak mobilization response to G-CSF to be assessed and plerixafor administered to the patients who have declared themselves as poor mobilizers. We propose that the preemptive plerixafor dosing strategy should be part of further pharmacoeconomic studies comparing this approach to up-front use of plerixafor for auto-SCT candidates.
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